A recent development in the healthcare industry has caught the attention of many stakeholders. On November 12, 2024, Johnson & Johnson made a bold move by filing a lawsuit against the Health Resources and Services Administration (HRSA) regarding the 340B Drug Pricing Program. This action was taken following a dispute over J&J’s plan to modify how it handles cost discounts for 340B purchases. The changes proposed by J&J and the response from HRSA shed light on the complexities within the program, with far-reaching implications for patients, hospitals, and drug manufacturers. It also underscores the pressing need for reforms in the administration of the 340B program.
The 340B program has faced criticism in the past due to a lack of transparency regarding the entities receiving discounts from drug manufacturers. This lack of oversight has raised concerns about potential abuse of the program. Recognizing these issues, J&J, along with other drug makers, devised a plan to address these challenges.
On August 23, 2024, J&J announced a new rebate model for two of its drugs, Stelara and Xarelto, specifically for Disproportionate Share Hospitals (DSH CEs). This model aimed to change the method of delivering discounts without affecting eligibility or the amount of the discount.
In response, HRSA issued warnings to J&J on September 17 and September 27, stating that the proposed rebate model had not received approval from the HHS Secretary. They threatened severe penalties, including the termination of J&J’s participation in 340B, Medicaid, and Medicare. Consequently, J&J decided to suspend the implementation of the rebate model in October and later filed a lawsuit against HRSA.
At the core of the lawsuit is the interpretation of the 340B statute, which does not dictate the specific delivery of discounts, leaving it to the discretion of the manufacturer. J&J’s objective in the lawsuit is to be allowed to implement their rebate model without facing the sanctions threatened by HRSA. The need for improved data, transparency, and eligible drug rebates to benefit disadvantaged patients is highlighted in this context.
An analysis of J&J’s proposed rebate model reveals potential benefits, such as enhanced transparency, real-time data access, and compliance with the Inflation Reduction Act’s Maximum Fair Price. While J&J’s approach has its merits, it has faced criticism from organizations like the American Hospital Association (AHA), which deemed the lawsuit “completely meritless.” Alternative models, like Eli Lilly’s cash replenishment model, are also emerging to streamline the discount process and enhance transparency.
These innovative models offer viable alternatives to the current 340B processes, prompting legislators to consider reforms. The recent Supreme Court ruling overturning the Chevron doctrine may influence the future direction of the 340B program by emphasizing statutory alignment and intent. Ultimately, comprehensive changes are needed in healthcare funding, but these proposals offer valuable insights into addressing existing flaws in the 340B program.
